nodes	percent_of_prediction	percent_of_DWPC	metapath
Naltrexone—UGT1A1—Irinotecan—stomach cancer	0.248	0.429	CbGbCtD
Naltrexone—ABCB1—Mitomycin—stomach cancer	0.192	0.332	CbGbCtD
Naltrexone—ABCB1—Irinotecan—stomach cancer	0.0492	0.0851	CbGbCtD
Naltrexone—ABCB1—Docetaxel—stomach cancer	0.036	0.0624	CbGbCtD
Naltrexone—ABCB1—Doxorubicin—stomach cancer	0.0269	0.0465	CbGbCtD
Naltrexone—ABCB1—Methotrexate—stomach cancer	0.026	0.045	CbGbCtD
Naltrexone—Anorexia—Capecitabine—stomach cancer	0.000215	0.000648	CcSEcCtD
Naltrexone—Angiopathy—Methotrexate—stomach cancer	0.000215	0.000646	CcSEcCtD
Naltrexone—Vomiting—Irinotecan—stomach cancer	0.000214	0.000646	CcSEcCtD
Naltrexone—Sinusitis—Doxorubicin—stomach cancer	0.000214	0.000645	CcSEcCtD
Naltrexone—Immune system disorder—Methotrexate—stomach cancer	0.000214	0.000643	CcSEcCtD
Naltrexone—Dizziness—Fluorouracil—stomach cancer	0.000214	0.000643	CcSEcCtD
Naltrexone—Mediastinal disorder—Methotrexate—stomach cancer	0.000213	0.000642	CcSEcCtD
Naltrexone—Rash—Irinotecan—stomach cancer	0.000213	0.00064	CcSEcCtD
Naltrexone—Dermatitis—Irinotecan—stomach cancer	0.000212	0.00064	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Docetaxel—stomach cancer	0.000212	0.00064	CcSEcCtD
Naltrexone—Chills—Methotrexate—stomach cancer	0.000212	0.000639	CcSEcCtD
Naltrexone—Headache—Irinotecan—stomach cancer	0.000211	0.000636	CcSEcCtD
Naltrexone—Insomnia—Docetaxel—stomach cancer	0.000211	0.000635	CcSEcCtD
Naltrexone—Paraesthesia—Docetaxel—stomach cancer	0.000209	0.000631	CcSEcCtD
Naltrexone—Alopecia—Methotrexate—stomach cancer	0.000209	0.000629	CcSEcCtD
Naltrexone—Dyspnoea—Docetaxel—stomach cancer	0.000208	0.000626	CcSEcCtD
Naltrexone—Somnolence—Docetaxel—stomach cancer	0.000207	0.000624	CcSEcCtD
Naltrexone—Mental disorder—Methotrexate—stomach cancer	0.000207	0.000624	CcSEcCtD
Naltrexone—Eye disorder—Epirubicin—stomach cancer	0.000207	0.000623	CcSEcCtD
Naltrexone—Tinnitus—Epirubicin—stomach cancer	0.000206	0.000622	CcSEcCtD
Naltrexone—Malnutrition—Methotrexate—stomach cancer	0.000206	0.00062	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Capecitabine—stomach cancer	0.000206	0.000619	CcSEcCtD
Naltrexone—Cardiac disorder—Epirubicin—stomach cancer	0.000205	0.000619	CcSEcCtD
Naltrexone—Vomiting—Fluorouracil—stomach cancer	0.000205	0.000619	CcSEcCtD
Naltrexone—Hepatitis—Doxorubicin—stomach cancer	0.000205	0.000617	CcSEcCtD
Naltrexone—Insomnia—Capecitabine—stomach cancer	0.000204	0.000615	CcSEcCtD
Naltrexone—Rash—Fluorouracil—stomach cancer	0.000204	0.000613	CcSEcCtD
Naltrexone—Dermatitis—Fluorouracil—stomach cancer	0.000203	0.000613	CcSEcCtD
Naltrexone—Pharyngitis—Doxorubicin—stomach cancer	0.000203	0.000612	CcSEcCtD
Naltrexone—Paraesthesia—Capecitabine—stomach cancer	0.000203	0.00061	CcSEcCtD
Naltrexone—Decreased appetite—Docetaxel—stomach cancer	0.000203	0.00061	CcSEcCtD
Naltrexone—Headache—Fluorouracil—stomach cancer	0.000202	0.000609	CcSEcCtD
Naltrexone—Dysgeusia—Methotrexate—stomach cancer	0.000202	0.000607	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Docetaxel—stomach cancer	0.000201	0.000606	CcSEcCtD
Naltrexone—Connective tissue disorder—Doxorubicin—stomach cancer	0.000201	0.000606	CcSEcCtD
Naltrexone—Dyspnoea—Capecitabine—stomach cancer	0.000201	0.000606	CcSEcCtD
Naltrexone—Fatigue—Docetaxel—stomach cancer	0.000201	0.000605	CcSEcCtD
Naltrexone—Angiopathy—Epirubicin—stomach cancer	0.000201	0.000605	CcSEcCtD
Naltrexone—Nausea—Irinotecan—stomach cancer	0.0002	0.000603	CcSEcCtD
Naltrexone—Immune system disorder—Epirubicin—stomach cancer	0.0002	0.000602	CcSEcCtD
Naltrexone—Mediastinal disorder—Epirubicin—stomach cancer	0.000199	0.000601	CcSEcCtD
Naltrexone—Pain—Docetaxel—stomach cancer	0.000199	0.0006	CcSEcCtD
Naltrexone—Constipation—Docetaxel—stomach cancer	0.000199	0.0006	CcSEcCtD
Naltrexone—Back pain—Methotrexate—stomach cancer	0.000199	0.0006	CcSEcCtD
Naltrexone—Chills—Epirubicin—stomach cancer	0.000199	0.000598	CcSEcCtD
Naltrexone—Decreased appetite—Capecitabine—stomach cancer	0.000196	0.000591	CcSEcCtD
Naltrexone—Alopecia—Epirubicin—stomach cancer	0.000196	0.000589	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Capecitabine—stomach cancer	0.000195	0.000587	CcSEcCtD
Naltrexone—Fatigue—Capecitabine—stomach cancer	0.000195	0.000586	CcSEcCtD
Naltrexone—Vision blurred—Methotrexate—stomach cancer	0.000194	0.000584	CcSEcCtD
Naltrexone—Mental disorder—Epirubicin—stomach cancer	0.000194	0.000584	CcSEcCtD
Naltrexone—Pain—Capecitabine—stomach cancer	0.000193	0.000581	CcSEcCtD
Naltrexone—Constipation—Capecitabine—stomach cancer	0.000193	0.000581	CcSEcCtD
Naltrexone—Malnutrition—Epirubicin—stomach cancer	0.000193	0.00058	CcSEcCtD
Naltrexone—Feeling abnormal—Docetaxel—stomach cancer	0.000192	0.000579	CcSEcCtD
Naltrexone—Nausea—Fluorouracil—stomach cancer	0.000192	0.000578	CcSEcCtD
Naltrexone—Eye disorder—Doxorubicin—stomach cancer	0.000191	0.000576	CcSEcCtD
Naltrexone—Ill-defined disorder—Methotrexate—stomach cancer	0.000191	0.000575	CcSEcCtD
Naltrexone—Tinnitus—Doxorubicin—stomach cancer	0.000191	0.000575	CcSEcCtD
Naltrexone—Gastrointestinal pain—Docetaxel—stomach cancer	0.000191	0.000574	CcSEcCtD
Naltrexone—Cardiac disorder—Doxorubicin—stomach cancer	0.00019	0.000572	CcSEcCtD
Naltrexone—Flatulence—Epirubicin—stomach cancer	0.00019	0.000572	CcSEcCtD
Naltrexone—Tension—Epirubicin—stomach cancer	0.000189	0.000569	CcSEcCtD
Naltrexone—Dysgeusia—Epirubicin—stomach cancer	0.000189	0.000568	CcSEcCtD
Naltrexone—Nervousness—Epirubicin—stomach cancer	0.000187	0.000564	CcSEcCtD
Naltrexone—Back pain—Epirubicin—stomach cancer	0.000186	0.000561	CcSEcCtD
Naltrexone—Feeling abnormal—Capecitabine—stomach cancer	0.000186	0.00056	CcSEcCtD
Naltrexone—Angiopathy—Doxorubicin—stomach cancer	0.000186	0.00056	CcSEcCtD
Naltrexone—Malaise—Methotrexate—stomach cancer	0.000186	0.000559	CcSEcCtD
Naltrexone—Muscle spasms—Epirubicin—stomach cancer	0.000185	0.000558	CcSEcCtD
Naltrexone—Immune system disorder—Doxorubicin—stomach cancer	0.000185	0.000557	CcSEcCtD
Naltrexone—Gastrointestinal pain—Capecitabine—stomach cancer	0.000185	0.000556	CcSEcCtD
Naltrexone—Mediastinal disorder—Doxorubicin—stomach cancer	0.000185	0.000556	CcSEcCtD
Naltrexone—Abdominal pain—Docetaxel—stomach cancer	0.000184	0.000555	CcSEcCtD
Naltrexone—Body temperature increased—Docetaxel—stomach cancer	0.000184	0.000555	CcSEcCtD
Naltrexone—Chills—Doxorubicin—stomach cancer	0.000184	0.000553	CcSEcCtD
Naltrexone—Vision blurred—Epirubicin—stomach cancer	0.000182	0.000547	CcSEcCtD
Naltrexone—Alopecia—Doxorubicin—stomach cancer	0.000181	0.000545	CcSEcCtD
Naltrexone—Cough—Methotrexate—stomach cancer	0.00018	0.000541	CcSEcCtD
Naltrexone—Mental disorder—Doxorubicin—stomach cancer	0.000179	0.00054	CcSEcCtD
Naltrexone—Urticaria—Capecitabine—stomach cancer	0.000179	0.00054	CcSEcCtD
Naltrexone—Ill-defined disorder—Epirubicin—stomach cancer	0.000179	0.000538	CcSEcCtD
Naltrexone—Abdominal pain—Capecitabine—stomach cancer	0.000178	0.000537	CcSEcCtD
Naltrexone—Body temperature increased—Capecitabine—stomach cancer	0.000178	0.000537	CcSEcCtD
Naltrexone—Convulsion—Methotrexate—stomach cancer	0.000178	0.000537	CcSEcCtD
Naltrexone—Malnutrition—Doxorubicin—stomach cancer	0.000178	0.000537	CcSEcCtD
Naltrexone—Agitation—Epirubicin—stomach cancer	0.000177	0.000533	CcSEcCtD
Naltrexone—Flatulence—Doxorubicin—stomach cancer	0.000176	0.000529	CcSEcCtD
Naltrexone—Arthralgia—Methotrexate—stomach cancer	0.000175	0.000528	CcSEcCtD
Naltrexone—Chest pain—Methotrexate—stomach cancer	0.000175	0.000528	CcSEcCtD
Naltrexone—Myalgia—Methotrexate—stomach cancer	0.000175	0.000528	CcSEcCtD
Naltrexone—Tension—Doxorubicin—stomach cancer	0.000175	0.000527	CcSEcCtD
Naltrexone—Dysgeusia—Doxorubicin—stomach cancer	0.000175	0.000526	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—stomach cancer	0.000174	0.000524	CcSEcCtD
Naltrexone—Malaise—Epirubicin—stomach cancer	0.000174	0.000523	CcSEcCtD
Naltrexone—Discomfort—Methotrexate—stomach cancer	0.000173	0.000522	CcSEcCtD
Naltrexone—Nervousness—Doxorubicin—stomach cancer	0.000173	0.000522	CcSEcCtD
Naltrexone—Syncope—Epirubicin—stomach cancer	0.000173	0.00052	CcSEcCtD
Naltrexone—Back pain—Doxorubicin—stomach cancer	0.000172	0.000519	CcSEcCtD
Naltrexone—Hypersensitivity—Docetaxel—stomach cancer	0.000172	0.000517	CcSEcCtD
Naltrexone—Muscle spasms—Doxorubicin—stomach cancer	0.000171	0.000516	CcSEcCtD
Naltrexone—Palpitations—Epirubicin—stomach cancer	0.00017	0.000513	CcSEcCtD
Naltrexone—Confusional state—Methotrexate—stomach cancer	0.000169	0.00051	CcSEcCtD
Naltrexone—Loss of consciousness—Epirubicin—stomach cancer	0.000169	0.00051	CcSEcCtD
Naltrexone—Cough—Epirubicin—stomach cancer	0.000168	0.000506	CcSEcCtD
Naltrexone—Anaphylactic shock—Methotrexate—stomach cancer	0.000168	0.000506	CcSEcCtD
Naltrexone—Vision blurred—Doxorubicin—stomach cancer	0.000168	0.000506	CcSEcCtD
Naltrexone—Asthenia—Docetaxel—stomach cancer	0.000167	0.000504	CcSEcCtD
Naltrexone—Convulsion—Epirubicin—stomach cancer	0.000167	0.000503	CcSEcCtD
Naltrexone—Infection—Methotrexate—stomach cancer	0.000167	0.000503	CcSEcCtD
Naltrexone—Hypertension—Epirubicin—stomach cancer	0.000166	0.000501	CcSEcCtD
Naltrexone—Hypersensitivity—Capecitabine—stomach cancer	0.000166	0.000501	CcSEcCtD
Naltrexone—Ill-defined disorder—Doxorubicin—stomach cancer	0.000165	0.000498	CcSEcCtD
Naltrexone—Pruritus—Docetaxel—stomach cancer	0.000165	0.000497	CcSEcCtD
Naltrexone—Nervous system disorder—Methotrexate—stomach cancer	0.000165	0.000496	CcSEcCtD
Naltrexone—Arthralgia—Epirubicin—stomach cancer	0.000164	0.000494	CcSEcCtD
Naltrexone—Myalgia—Epirubicin—stomach cancer	0.000164	0.000494	CcSEcCtD
Naltrexone—Chest pain—Epirubicin—stomach cancer	0.000164	0.000494	CcSEcCtD
Naltrexone—Agitation—Doxorubicin—stomach cancer	0.000164	0.000493	CcSEcCtD
Naltrexone—Anxiety—Epirubicin—stomach cancer	0.000163	0.000492	CcSEcCtD
Naltrexone—Skin disorder—Methotrexate—stomach cancer	0.000163	0.000492	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—stomach cancer	0.000163	0.000491	CcSEcCtD
Naltrexone—Hyperhidrosis—Methotrexate—stomach cancer	0.000162	0.000489	CcSEcCtD
Naltrexone—Discomfort—Epirubicin—stomach cancer	0.000162	0.000488	CcSEcCtD
Naltrexone—Asthenia—Capecitabine—stomach cancer	0.000162	0.000488	CcSEcCtD
Naltrexone—Malaise—Doxorubicin—stomach cancer	0.000161	0.000484	CcSEcCtD
Naltrexone—Dry mouth—Epirubicin—stomach cancer	0.00016	0.000483	CcSEcCtD
Naltrexone—Anorexia—Methotrexate—stomach cancer	0.00016	0.000482	CcSEcCtD
Naltrexone—Syncope—Doxorubicin—stomach cancer	0.00016	0.000482	CcSEcCtD
Naltrexone—Pruritus—Capecitabine—stomach cancer	0.00016	0.000481	CcSEcCtD
Naltrexone—Diarrhoea—Docetaxel—stomach cancer	0.00016	0.00048	CcSEcCtD
Naltrexone—Confusional state—Epirubicin—stomach cancer	0.000159	0.000478	CcSEcCtD
Naltrexone—Palpitations—Doxorubicin—stomach cancer	0.000158	0.000475	CcSEcCtD
Naltrexone—Anaphylactic shock—Epirubicin—stomach cancer	0.000157	0.000474	CcSEcCtD
Naltrexone—Oedema—Epirubicin—stomach cancer	0.000157	0.000474	CcSEcCtD
Naltrexone—Loss of consciousness—Doxorubicin—stomach cancer	0.000157	0.000472	CcSEcCtD
Naltrexone—Infection—Epirubicin—stomach cancer	0.000156	0.000471	CcSEcCtD
Naltrexone—Cough—Doxorubicin—stomach cancer	0.000156	0.000469	CcSEcCtD
Naltrexone—Shock—Epirubicin—stomach cancer	0.000155	0.000466	CcSEcCtD
Naltrexone—Convulsion—Doxorubicin—stomach cancer	0.000154	0.000465	CcSEcCtD
Naltrexone—Diarrhoea—Capecitabine—stomach cancer	0.000154	0.000465	CcSEcCtD
Naltrexone—Nervous system disorder—Epirubicin—stomach cancer	0.000154	0.000464	CcSEcCtD
Naltrexone—Dizziness—Docetaxel—stomach cancer	0.000154	0.000464	CcSEcCtD
Naltrexone—Hypertension—Doxorubicin—stomach cancer	0.000154	0.000464	CcSEcCtD
Naltrexone—Tachycardia—Epirubicin—stomach cancer	0.000153	0.000462	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Methotrexate—stomach cancer	0.000153	0.000461	CcSEcCtD
Naltrexone—Skin disorder—Epirubicin—stomach cancer	0.000153	0.00046	CcSEcCtD
Naltrexone—Hyperhidrosis—Epirubicin—stomach cancer	0.000152	0.000458	CcSEcCtD
Naltrexone—Insomnia—Methotrexate—stomach cancer	0.000152	0.000458	CcSEcCtD
Naltrexone—Chest pain—Doxorubicin—stomach cancer	0.000152	0.000457	CcSEcCtD
Naltrexone—Myalgia—Doxorubicin—stomach cancer	0.000152	0.000457	CcSEcCtD
Naltrexone—Arthralgia—Doxorubicin—stomach cancer	0.000152	0.000457	CcSEcCtD
Naltrexone—Anxiety—Doxorubicin—stomach cancer	0.000151	0.000456	CcSEcCtD
Naltrexone—Paraesthesia—Methotrexate—stomach cancer	0.000151	0.000454	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—stomach cancer	0.000151	0.000454	CcSEcCtD
Naltrexone—Discomfort—Doxorubicin—stomach cancer	0.00015	0.000452	CcSEcCtD
Naltrexone—Anorexia—Epirubicin—stomach cancer	0.00015	0.000451	CcSEcCtD
Naltrexone—Dyspnoea—Methotrexate—stomach cancer	0.00015	0.000451	CcSEcCtD
Naltrexone—Somnolence—Methotrexate—stomach cancer	0.000149	0.00045	CcSEcCtD
Naltrexone—Dizziness—Capecitabine—stomach cancer	0.000149	0.00045	CcSEcCtD
Naltrexone—Dry mouth—Doxorubicin—stomach cancer	0.000148	0.000447	CcSEcCtD
Naltrexone—Vomiting—Docetaxel—stomach cancer	0.000148	0.000446	CcSEcCtD
Naltrexone—Rash—Docetaxel—stomach cancer	0.000147	0.000443	CcSEcCtD
Naltrexone—Dermatitis—Docetaxel—stomach cancer	0.000147	0.000442	CcSEcCtD
Naltrexone—Confusional state—Doxorubicin—stomach cancer	0.000147	0.000442	CcSEcCtD
Naltrexone—Decreased appetite—Methotrexate—stomach cancer	0.000146	0.00044	CcSEcCtD
Naltrexone—Headache—Docetaxel—stomach cancer	0.000146	0.00044	CcSEcCtD
Naltrexone—Anaphylactic shock—Doxorubicin—stomach cancer	0.000145	0.000438	CcSEcCtD
Naltrexone—Oedema—Doxorubicin—stomach cancer	0.000145	0.000438	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Methotrexate—stomach cancer	0.000145	0.000437	CcSEcCtD
Naltrexone—Fatigue—Methotrexate—stomach cancer	0.000145	0.000436	CcSEcCtD
Naltrexone—Infection—Doxorubicin—stomach cancer	0.000145	0.000435	CcSEcCtD
Naltrexone—Pain—Methotrexate—stomach cancer	0.000144	0.000433	CcSEcCtD
Naltrexone—Vomiting—Capecitabine—stomach cancer	0.000144	0.000432	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Epirubicin—stomach cancer	0.000143	0.000432	CcSEcCtD
Naltrexone—Shock—Doxorubicin—stomach cancer	0.000143	0.000431	CcSEcCtD
Naltrexone—Nervous system disorder—Doxorubicin—stomach cancer	0.000143	0.00043	CcSEcCtD
Naltrexone—Rash—Capecitabine—stomach cancer	0.000142	0.000429	CcSEcCtD
Naltrexone—Insomnia—Epirubicin—stomach cancer	0.000142	0.000428	CcSEcCtD
Naltrexone—Dermatitis—Capecitabine—stomach cancer	0.000142	0.000428	CcSEcCtD
Naltrexone—Tachycardia—Doxorubicin—stomach cancer	0.000142	0.000428	CcSEcCtD
Naltrexone—Headache—Capecitabine—stomach cancer	0.000141	0.000426	CcSEcCtD
Naltrexone—Skin disorder—Doxorubicin—stomach cancer	0.000141	0.000426	CcSEcCtD
Naltrexone—Paraesthesia—Epirubicin—stomach cancer	0.000141	0.000425	CcSEcCtD
Naltrexone—Hyperhidrosis—Doxorubicin—stomach cancer	0.000141	0.000424	CcSEcCtD
Naltrexone—Dyspnoea—Epirubicin—stomach cancer	0.00014	0.000422	CcSEcCtD
Naltrexone—Somnolence—Epirubicin—stomach cancer	0.00014	0.000421	CcSEcCtD
Naltrexone—Anorexia—Doxorubicin—stomach cancer	0.000139	0.000418	CcSEcCtD
Naltrexone—Nausea—Docetaxel—stomach cancer	0.000138	0.000417	CcSEcCtD
Naltrexone—Feeling abnormal—Methotrexate—stomach cancer	0.000138	0.000417	CcSEcCtD
Naltrexone—Gastrointestinal pain—Methotrexate—stomach cancer	0.000137	0.000414	CcSEcCtD
Naltrexone—Decreased appetite—Epirubicin—stomach cancer	0.000137	0.000412	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Epirubicin—stomach cancer	0.000136	0.000409	CcSEcCtD
Naltrexone—Fatigue—Epirubicin—stomach cancer	0.000136	0.000408	CcSEcCtD
Naltrexone—Pain—Epirubicin—stomach cancer	0.000134	0.000405	CcSEcCtD
Naltrexone—Constipation—Epirubicin—stomach cancer	0.000134	0.000405	CcSEcCtD
Naltrexone—Nausea—Capecitabine—stomach cancer	0.000134	0.000404	CcSEcCtD
Naltrexone—Urticaria—Methotrexate—stomach cancer	0.000133	0.000402	CcSEcCtD
Naltrexone—Abdominal pain—Methotrexate—stomach cancer	0.000133	0.0004	CcSEcCtD
Naltrexone—Body temperature increased—Methotrexate—stomach cancer	0.000133	0.0004	CcSEcCtD
Naltrexone—Buprenorphine—CYP2A6—stomach cancer	0.000133	0.721	CrCbGaD
Naltrexone—Musculoskeletal discomfort—Doxorubicin—stomach cancer	0.000133	0.000399	CcSEcCtD
Naltrexone—Insomnia—Doxorubicin—stomach cancer	0.000132	0.000396	CcSEcCtD
Naltrexone—Paraesthesia—Doxorubicin—stomach cancer	0.000131	0.000394	CcSEcCtD
Naltrexone—Dyspnoea—Doxorubicin—stomach cancer	0.00013	0.000391	CcSEcCtD
Naltrexone—Feeling abnormal—Epirubicin—stomach cancer	0.00013	0.00039	CcSEcCtD
Naltrexone—Somnolence—Doxorubicin—stomach cancer	0.000129	0.00039	CcSEcCtD
Naltrexone—Gastrointestinal pain—Epirubicin—stomach cancer	0.000129	0.000387	CcSEcCtD
Naltrexone—Decreased appetite—Doxorubicin—stomach cancer	0.000126	0.000381	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Doxorubicin—stomach cancer	0.000126	0.000378	CcSEcCtD
Naltrexone—Fatigue—Doxorubicin—stomach cancer	0.000125	0.000378	CcSEcCtD
Naltrexone—Urticaria—Epirubicin—stomach cancer	0.000125	0.000376	CcSEcCtD
Naltrexone—Constipation—Doxorubicin—stomach cancer	0.000124	0.000375	CcSEcCtD
Naltrexone—Pain—Doxorubicin—stomach cancer	0.000124	0.000375	CcSEcCtD
Naltrexone—Body temperature increased—Epirubicin—stomach cancer	0.000124	0.000374	CcSEcCtD
Naltrexone—Abdominal pain—Epirubicin—stomach cancer	0.000124	0.000374	CcSEcCtD
Naltrexone—Hypersensitivity—Methotrexate—stomach cancer	0.000124	0.000373	CcSEcCtD
Naltrexone—Asthenia—Methotrexate—stomach cancer	0.000121	0.000363	CcSEcCtD
Naltrexone—Feeling abnormal—Doxorubicin—stomach cancer	0.00012	0.000361	CcSEcCtD
Naltrexone—Gastrointestinal pain—Doxorubicin—stomach cancer	0.000119	0.000358	CcSEcCtD
Naltrexone—Pruritus—Methotrexate—stomach cancer	0.000119	0.000358	CcSEcCtD
Naltrexone—Hypersensitivity—Epirubicin—stomach cancer	0.000116	0.000349	CcSEcCtD
Naltrexone—Urticaria—Doxorubicin—stomach cancer	0.000116	0.000348	CcSEcCtD
Naltrexone—Body temperature increased—Doxorubicin—stomach cancer	0.000115	0.000346	CcSEcCtD
Naltrexone—Abdominal pain—Doxorubicin—stomach cancer	0.000115	0.000346	CcSEcCtD
Naltrexone—Diarrhoea—Methotrexate—stomach cancer	0.000115	0.000346	CcSEcCtD
Naltrexone—Asthenia—Epirubicin—stomach cancer	0.000113	0.00034	CcSEcCtD
Naltrexone—Pruritus—Epirubicin—stomach cancer	0.000111	0.000335	CcSEcCtD
Naltrexone—Dizziness—Methotrexate—stomach cancer	0.000111	0.000335	CcSEcCtD
Naltrexone—Diarrhoea—Epirubicin—stomach cancer	0.000108	0.000324	CcSEcCtD
Naltrexone—Hypersensitivity—Doxorubicin—stomach cancer	0.000107	0.000323	CcSEcCtD
Naltrexone—Vomiting—Methotrexate—stomach cancer	0.000107	0.000322	CcSEcCtD
Naltrexone—Rash—Methotrexate—stomach cancer	0.000106	0.000319	CcSEcCtD
Naltrexone—Dermatitis—Methotrexate—stomach cancer	0.000106	0.000319	CcSEcCtD
Naltrexone—Headache—Methotrexate—stomach cancer	0.000105	0.000317	CcSEcCtD
Naltrexone—Asthenia—Doxorubicin—stomach cancer	0.000104	0.000314	CcSEcCtD
Naltrexone—Dizziness—Epirubicin—stomach cancer	0.000104	0.000313	CcSEcCtD
Naltrexone—Pruritus—Doxorubicin—stomach cancer	0.000103	0.00031	CcSEcCtD
Naltrexone—Vomiting—Epirubicin—stomach cancer	0.0001	0.000301	CcSEcCtD
Naltrexone—Nausea—Methotrexate—stomach cancer	9.98e-05	0.000301	CcSEcCtD
Naltrexone—Diarrhoea—Doxorubicin—stomach cancer	9.96e-05	0.0003	CcSEcCtD
Naltrexone—Rash—Epirubicin—stomach cancer	9.91e-05	0.000299	CcSEcCtD
Naltrexone—Dermatitis—Epirubicin—stomach cancer	9.91e-05	0.000298	CcSEcCtD
Naltrexone—Headache—Epirubicin—stomach cancer	9.85e-05	0.000297	CcSEcCtD
Naltrexone—Dizziness—Doxorubicin—stomach cancer	9.62e-05	0.00029	CcSEcCtD
Naltrexone—Nausea—Epirubicin—stomach cancer	9.34e-05	0.000281	CcSEcCtD
Naltrexone—Vomiting—Doxorubicin—stomach cancer	9.25e-05	0.000279	CcSEcCtD
Naltrexone—Rash—Doxorubicin—stomach cancer	9.17e-05	0.000276	CcSEcCtD
Naltrexone—Dermatitis—Doxorubicin—stomach cancer	9.17e-05	0.000276	CcSEcCtD
Naltrexone—Headache—Doxorubicin—stomach cancer	9.11e-05	0.000275	CcSEcCtD
Naltrexone—Nausea—Doxorubicin—stomach cancer	8.64e-05	0.00026	CcSEcCtD
Naltrexone—Naloxone—ALB—stomach cancer	5.14e-05	0.279	CrCbGaD
Naltrexone—OPRM1—Signaling by GPCR—PPP2R1A—stomach cancer	4.43e-05	0.000493	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PRKAA1—stomach cancer	4.41e-05	0.000491	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—AKR1C3—stomach cancer	4.36e-05	0.000485	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HSPB1—stomach cancer	4.33e-05	0.000482	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—AGTR2—stomach cancer	4.33e-05	0.000482	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—BMP2—stomach cancer	4.29e-05	0.000477	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—F2R—stomach cancer	4.29e-05	0.000477	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—RBP4—stomach cancer	4.26e-05	0.000474	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—CXCL8—stomach cancer	4.26e-05	0.000474	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—RPS6—stomach cancer	4.25e-05	0.000473	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ENO1—stomach cancer	4.25e-05	0.000472	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—AKR1C3—stomach cancer	4.22e-05	0.000469	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—PRKCB—stomach cancer	4.18e-05	0.000465	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HTR1A—stomach cancer	4.17e-05	0.000464	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—IL6ST—stomach cancer	4.17e-05	0.000464	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NDUFA2—stomach cancer	4.16e-05	0.000463	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CA1—stomach cancer	4.16e-05	0.000463	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—FBP1—stomach cancer	4.16e-05	0.000463	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CKB—stomach cancer	4.16e-05	0.000463	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—stomach cancer	4.11e-05	0.000457	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—PRKCB—stomach cancer	4.04e-05	0.000449	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ANXA1—stomach cancer	4.03e-05	0.000448	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—stomach cancer	4.02e-05	0.000447	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PLIN2—stomach cancer	3.91e-05	0.000435	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—HBEGF—stomach cancer	3.91e-05	0.000435	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ADRB1—stomach cancer	3.9e-05	0.000434	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CA2—stomach cancer	3.81e-05	0.000423	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—stomach cancer	3.8e-05	0.000423	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CD44—stomach cancer	3.77e-05	0.000419	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—RPS6—stomach cancer	3.73e-05	0.000415	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—IL6R—stomach cancer	3.72e-05	0.000414	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NT5E—stomach cancer	3.71e-05	0.000413	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PGAM1—stomach cancer	3.71e-05	0.000413	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—RHOA—stomach cancer	3.7e-05	0.000411	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—PRKCB—stomach cancer	3.67e-05	0.000408	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—AGTR2—stomach cancer	3.66e-05	0.000407	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HSPB1—stomach cancer	3.66e-05	0.000407	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—IL6ST—stomach cancer	3.65e-05	0.000406	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—stomach cancer	3.63e-05	0.000404	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—BMP2—stomach cancer	3.62e-05	0.000403	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—F2R—stomach cancer	3.62e-05	0.000403	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—stomach cancer	3.62e-05	0.000403	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—ADRB2—stomach cancer	3.61e-05	0.000401	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—AKR1C3—stomach cancer	3.56e-05	0.000396	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ALDH7A1—stomach cancer	3.54e-05	0.000394	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PLCE1—stomach cancer	3.54e-05	0.000394	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PPP2R1A—stomach cancer	3.53e-05	0.000393	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HTR1A—stomach cancer	3.53e-05	0.000392	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—stomach cancer	3.51e-05	0.00039	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HBEGF—stomach cancer	3.43e-05	0.000381	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—stomach cancer	3.43e-05	0.000381	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—PRKCB—stomach cancer	3.41e-05	0.00038	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ANXA1—stomach cancer	3.41e-05	0.000379	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—UMPS—stomach cancer	3.39e-05	0.000377	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—RHOA—stomach cancer	3.36e-05	0.000374	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ADRB1—stomach cancer	3.3e-05	0.000367	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—SMAD4—stomach cancer	3.28e-05	0.000365	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—IL6R—stomach cancer	3.26e-05	0.000363	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—CXCL8—stomach cancer	3.25e-05	0.000361	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—RHOA—stomach cancer	3.24e-05	0.000361	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PPP2R1A—stomach cancer	3.2e-05	0.000356	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—stomach cancer	3.16e-05	0.000352	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ADRB2—stomach cancer	3.16e-05	0.000352	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PDHA1—stomach cancer	3.15e-05	0.000351	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ECHS1—stomach cancer	3.15e-05	0.000351	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—RPS6—stomach cancer	3.15e-05	0.000351	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GSTP1—stomach cancer	3.14e-05	0.000349	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—FYN—stomach cancer	3.12e-05	0.000347	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PRKCB—stomach cancer	3.1e-05	0.000345	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PPP2R1A—stomach cancer	3.1e-05	0.000345	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—HMOX1—stomach cancer	3.1e-05	0.000345	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—IL6ST—stomach cancer	3.09e-05	0.000344	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—HMOX1—stomach cancer	3.03e-05	0.000338	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—stomach cancer	2.99e-05	0.000333	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—TYMP—stomach cancer	2.97e-05	0.00033	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—FADS1—stomach cancer	2.97e-05	0.00033	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CXCL8—stomach cancer	2.95e-05	0.000328	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—RHOA—stomach cancer	2.95e-05	0.000328	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—FGFR2—stomach cancer	2.92e-05	0.000325	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—TYMS—stomach cancer	2.92e-05	0.000325	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—stomach cancer	2.91e-05	0.000324	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HBEGF—stomach cancer	2.9e-05	0.000322	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GSTM1—stomach cancer	2.89e-05	0.000321	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—SMAD4—stomach cancer	2.88e-05	0.00032	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—CXCL8—stomach cancer	2.85e-05	0.000317	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—stomach cancer	2.85e-05	0.000317	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—stomach cancer	2.85e-05	0.000317	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—SREBF2—stomach cancer	2.78e-05	0.000309	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—IL6R—stomach cancer	2.76e-05	0.000306	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—RORA—stomach cancer	2.74e-05	0.000305	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—RHOA—stomach cancer	2.74e-05	0.000305	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—FYN—stomach cancer	2.73e-05	0.000304	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ERCC2—stomach cancer	2.71e-05	0.000302	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—stomach cancer	2.71e-05	0.000302	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—stomach cancer	2.69e-05	0.000299	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IRS2—stomach cancer	2.68e-05	0.000298	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ADRB2—stomach cancer	2.67e-05	0.000297	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PPP2R1A—stomach cancer	2.62e-05	0.000291	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CAV1—stomach cancer	2.6e-05	0.000289	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—APOA1—stomach cancer	2.59e-05	0.000288	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CXCL8—stomach cancer	2.59e-05	0.000288	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ALDOB—stomach cancer	2.57e-05	0.000286	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—FGFR2—stomach cancer	2.56e-05	0.000285	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—MTHFR—stomach cancer	2.55e-05	0.000284	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—RHOA—stomach cancer	2.49e-05	0.000277	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PRKCB—stomach cancer	2.47e-05	0.000275	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—stomach cancer	2.47e-05	0.000275	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IL6ST—stomach cancer	2.46e-05	0.000274	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—SMAD4—stomach cancer	2.43e-05	0.00027	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CXCL8—stomach cancer	2.41e-05	0.000268	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ALOX5—stomach cancer	2.39e-05	0.000266	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—stomach cancer	2.39e-05	0.000266	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—APC—stomach cancer	2.37e-05	0.000263	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CAV1—stomach cancer	2.35e-05	0.000262	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—DPYD—stomach cancer	2.35e-05	0.000262	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IRS2—stomach cancer	2.35e-05	0.000261	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—APOA1—stomach cancer	2.35e-05	0.000261	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—FYN—stomach cancer	2.31e-05	0.000257	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—APOA1—stomach cancer	2.3e-05	0.000256	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CAV1—stomach cancer	2.28e-05	0.000253	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—APOA1—stomach cancer	2.27e-05	0.000253	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—MAPK3—stomach cancer	2.27e-05	0.000252	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IL6R—stomach cancer	2.2e-05	0.000244	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CXCL8—stomach cancer	2.19e-05	0.000243	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—FGFR2—stomach cancer	2.17e-05	0.000241	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PRKCB—stomach cancer	2.17e-05	0.000241	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IL6ST—stomach cancer	2.16e-05	0.00024	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—MAPK1—stomach cancer	2.16e-05	0.00024	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—EGFR—stomach cancer	2.16e-05	0.00024	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTT1—stomach cancer	2.08e-05	0.000231	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—APC—stomach cancer	2.07e-05	0.000231	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PPARG—stomach cancer	2.07e-05	0.00023	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—PIK3CA—stomach cancer	2.06e-05	0.000229	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—SERPINE1—stomach cancer	2.06e-05	0.000229	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP2A6—stomach cancer	2.06e-05	0.000229	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—KRAS—stomach cancer	2.04e-05	0.000226	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—AKR1C3—stomach cancer	2e-05	0.000222	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—MAPK3—stomach cancer	1.99e-05	0.000221	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IRS2—stomach cancer	1.98e-05	0.000221	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—RHOA—stomach cancer	1.98e-05	0.000221	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NOS3—stomach cancer	1.96e-05	0.000218	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ENO1—stomach cancer	1.95e-05	0.000217	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IL6R—stomach cancer	1.93e-05	0.000214	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CAV1—stomach cancer	1.92e-05	0.000214	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—APOA1—stomach cancer	1.92e-05	0.000214	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—MAPK1—stomach cancer	1.89e-05	0.00021	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—EGFR—stomach cancer	1.89e-05	0.00021	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—PIK3CA—stomach cancer	1.87e-05	0.000208	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ALB—stomach cancer	1.86e-05	0.000207	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—ERBB2—stomach cancer	1.84e-05	0.000204	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PRKCB—stomach cancer	1.83e-05	0.000204	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IL6ST—stomach cancer	1.82e-05	0.000203	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—ALB—stomach cancer	1.82e-05	0.000203	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—PIK3CA—stomach cancer	1.81e-05	0.000201	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—SERPINE1—stomach cancer	1.8e-05	0.000201	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—KRAS—stomach cancer	1.79e-05	0.000199	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—NOS3—stomach cancer	1.78e-05	0.000198	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—APC—stomach cancer	1.75e-05	0.000195	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CXCL8—stomach cancer	1.74e-05	0.000194	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—RHOA—stomach cancer	1.74e-05	0.000194	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—HRAS—stomach cancer	1.73e-05	0.000192	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CD44—stomach cancer	1.73e-05	0.000192	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NOS3—stomach cancer	1.72e-05	0.000192	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CDKN1B—stomach cancer	1.7e-05	0.000189	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—MAPK3—stomach cancer	1.68e-05	0.000187	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—IL6—stomach cancer	1.66e-05	0.000184	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—PIK3CA—stomach cancer	1.64e-05	0.000182	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IL6R—stomach cancer	1.63e-05	0.000181	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PTGS2—stomach cancer	1.63e-05	0.000181	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CCND1—stomach cancer	1.62e-05	0.00018	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—JUN—stomach cancer	1.62e-05	0.00018	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ERBB2—stomach cancer	1.61e-05	0.000179	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—MAPK1—stomach cancer	1.6e-05	0.000178	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—EGFR—stomach cancer	1.6e-05	0.000178	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MMP9—stomach cancer	1.58e-05	0.000175	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CDKN1A—stomach cancer	1.57e-05	0.000175	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MAPK8—stomach cancer	1.53e-05	0.00017	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CXCL8—stomach cancer	1.53e-05	0.00017	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—PIK3CA—stomach cancer	1.53e-05	0.00017	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—SERPINE1—stomach cancer	1.52e-05	0.00017	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—HRAS—stomach cancer	1.52e-05	0.000169	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—KRAS—stomach cancer	1.51e-05	0.000168	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CDKN1B—stomach cancer	1.49e-05	0.000166	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—RHOA—stomach cancer	1.47e-05	0.000164	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PPP2R1A—stomach cancer	1.47e-05	0.000163	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NOS3—stomach cancer	1.46e-05	0.000162	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—IL6—stomach cancer	1.45e-05	0.000162	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTP1—stomach cancer	1.44e-05	0.00016	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCND1—stomach cancer	1.42e-05	0.000158	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—HMOX1—stomach cancer	1.42e-05	0.000158	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—JUN—stomach cancer	1.42e-05	0.000158	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—VEGFA—stomach cancer	1.41e-05	0.000157	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—STAT3—stomach cancer	1.4e-05	0.000156	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PIK3CA—stomach cancer	1.39e-05	0.000154	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MMP9—stomach cancer	1.38e-05	0.000154	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CDKN1A—stomach cancer	1.38e-05	0.000153	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ERBB2—stomach cancer	1.36e-05	0.000151	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MAPK8—stomach cancer	1.34e-05	0.000149	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—TYMS—stomach cancer	1.34e-05	0.000149	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MAPK3—stomach cancer	1.34e-05	0.000149	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTM1—stomach cancer	1.32e-05	0.000147	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MYC—stomach cancer	1.3e-05	0.000145	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CXCL8—stomach cancer	1.29e-05	0.000144	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—HRAS—stomach cancer	1.28e-05	0.000143	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MAPK1—stomach cancer	1.27e-05	0.000142	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—EGFR—stomach cancer	1.27e-05	0.000142	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CDKN1B—stomach cancer	1.26e-05	0.00014	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ERCC2—stomach cancer	1.25e-05	0.000139	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—VEGFA—stomach cancer	1.24e-05	0.000138	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—STAT3—stomach cancer	1.23e-05	0.000137	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—IL6—stomach cancer	1.23e-05	0.000137	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—KRAS—stomach cancer	1.2e-05	0.000134	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCND1—stomach cancer	1.2e-05	0.000134	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—JUN—stomach cancer	1.2e-05	0.000133	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MAPK3—stomach cancer	1.17e-05	0.000131	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—MTHFR—stomach cancer	1.17e-05	0.00013	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MMP9—stomach cancer	1.17e-05	0.00013	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CDKN1A—stomach cancer	1.16e-05	0.000129	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MYC—stomach cancer	1.14e-05	0.000127	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MAPK8—stomach cancer	1.14e-05	0.000126	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MAPK1—stomach cancer	1.12e-05	0.000124	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—EGFR—stomach cancer	1.12e-05	0.000124	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PIK3CA—stomach cancer	1.1e-05	0.000123	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CAV1—stomach cancer	1.08e-05	0.00012	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—APOA1—stomach cancer	1.08e-05	0.00012	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TP53—stomach cancer	1.07e-05	0.000119	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—KRAS—stomach cancer	1.05e-05	0.000117	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—VEGFA—stomach cancer	1.05e-05	0.000117	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—STAT3—stomach cancer	1.04e-05	0.000115	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—HRAS—stomach cancer	1.02e-05	0.000114	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PIK3CA—stomach cancer	1e-05	0.000111	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MAPK3—stomach cancer	9.92e-06	0.00011	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IL6—stomach cancer	9.78e-06	0.000109	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PIK3CA—stomach cancer	9.69e-06	0.000108	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MYC—stomach cancer	9.65e-06	0.000107	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PPARG—stomach cancer	9.49e-06	0.000106	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MAPK1—stomach cancer	9.44e-06	0.000105	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—EGFR—stomach cancer	9.43e-06	0.000105	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TP53—stomach cancer	9.37e-06	0.000104	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HRAS—stomach cancer	8.96e-06	9.97e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—KRAS—stomach cancer	8.91e-06	9.91e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IL6—stomach cancer	8.58e-06	9.54e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ALB—stomach cancer	8.54e-06	9.49e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PIK3CA—stomach cancer	8.19e-06	9.11e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NOS3—stomach cancer	8.16e-06	9.08e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TP53—stomach cancer	7.92e-06	8.81e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HRAS—stomach cancer	7.58e-06	8.43e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PTGS2—stomach cancer	7.47e-06	8.31e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IL6—stomach cancer	7.25e-06	8.07e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PIK3CA—stomach cancer	4.59e-06	5.11e-05	CbGpPWpGaD
